End Stage Renal Disease Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19 – Eurowire

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the End Stage Renal Disease market.

Trusted Business Insights presents an updated and Latest Study on End Stage Renal Disease Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the End Stage Renal Disease market during the forecast period (2020-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ End Stage Renal Disease Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Report Overview: End Stage Renal Disease Market

The global end stage renal disease market size was valued at USD 57.9 billion in 2020 and is anticipated to expand at a CAGR of 11.3% over the forecast period 2021-2027. Increasing number of patients suffering from renal or kidney failure and introduction of technologically advanced products, such as low maintenance dialysis equipment and artificial kidney, are the major factors expected to drive the market.

Any condition that causes reduced kidney function leads to chronic kidney disease (CKD), which may develop over a period and lead to end stage renal disease (ESRD), where kidney can no longer function on their own. It is also termed as kidney or renal failure. Factors contributing to the formation of end stage renal disease include hypertension, diabetes, smoking, and older age. The most common cause is diabetes, whereas hypertension (high blood pressure) is the second most frequent cause of end stage kidney disease. The treatment of end stage renal disease or CKD includes kidney transplantation or dialysis to stay alive.

Chronic kidney disease is one of the major reasons behind the increase in the number of renal failure patients. According to the National Kidney Foundation (NKD), approximately 10% of the global population suffers from CKD and millions die each year. As per the estimations of the NKD, the number of cases will increase in the developing countries, such as China and India, especially among the elderly people, since the geriatric population is more prone to renal problems. The number of patients continues to increase at a rate of 5-7% per year and receives treatment with a kidney transplant or dialysis to stay alive. Chronic kidney disease is more common in women (15%) than men (12%). Increasing number of patients suffering from hypertension and diabetes is another key factor driving the overall market. Approximately, one-third of the population with diabetes develop chronic kidney disease and it is the most common cause of end stage renal disease. Hypertension is mainly caused due to high blood pressure, which significantly increases the risk of end stage renal disease. According to WHO facts 2019, around 1.13 billion people worldwide have hypertension. Diabetes and hypertension were responsible for nearly 75% of end stage renal disease from 2014-2016. Diabetes is the primary cause of advanced renal failure, followed by hypertension, which is estimated to affect around 1 billion individuals globally. Thus, increasing number of patients suffering from hypertension and diabetes is majorly driving the market for end stage renal disease. China, the U.S., Taiwan, Japan, Germany, France, Belgium, Africa, and Rest of Asia Pacific have witnessed the highest prevalence of end stage renal disease in the recent years. As per the estimation of Centers for Disease Control and Prevention (CDC) report 2016, in U.S., around 125,000 people received treatment for end stage kidney disease, whereas approximately 726,000 were on dialysis or living with a kidney transplant. Furthermore, it reported that around 80 million people, which is 1 in 3 American adults is at risk for chronic kidney disease and it is the ninth leading cause of death in the U.S. Therefore, such high prevalence of end stage kidney disease is anticipated to boost the market growth over the forecast period.

Increasing incidence of end stage renal diseases in the developed and developing countries has driven the launch of technologically advanced products in the market for end stage kidney disease. For instance, in February 2014, the first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 was approved by the U.S. FDA. This innovation is intended to obtain satisfactory and effective results from patients suffering from end stage renal failure. Thus, technological advancements in the treatment of end stage renal disease is another factor expediting the overall market growth.

Treatment Insights: End Stage Renal Disease Market

The dialysis segment lead the end stage renal disease market in 2019. Dialysis is more convenient and easier to obtain for a patient with end stage kidney disease and the whole process can be done at a dialysis center or at home. Moreover, patients dont have to depend on donor organs, which are available in a very limited number as compared to dialysis equipment. Patients in developing, highly populous, or low-income countries can only obtain dialysis as compared to transplantation procedures. Thus, benefits offered by dialysis are expected to fuel the segment growth.

Moreover, growing awareness about end stage renal diseases and unhealthy lifestyle are driving the segment. For instance, DaVita Inc., a public community, and other related organizations are committed to raise global awareness regarding renal failure. These organizations organize awareness education programs, such as kidney smart classes, wherein kidney care experts provide education about the reasons of kidney or renal failure, lifestyle choices, CKD basics, healthy diets as well as nutrition information.

The National Institute of Health (NIH) has declared the month of March as National Kidney Month in order to help raise awareness regarding kidney diseases. Thus, presence of numerous awareness initiatives is expected to result in the increase in the number of patients willing to test for end stage renal disease. Growing patient population with chronic kidney disease shall therefore opt for peritoneal dialysis or hemodialysis, which will further increase the demand for the treatment of end stage kidney disease.

Regional Insights: End Stage Renal Disease Market

Asia Pacific lead the market in 2019 due to increasing healthcare spending, government initiatives, rising awareness campaigns regarding CKD, technologically enhanced products, and presence of newly-established state-of-the-art healthcare facilities in the region. High blood pressure and diabetes are the major risk factors for the development of kidney disease. Asia Pacific is estimated to have the largest population of diabetics and hypertension patients worldwide, closely followed by Africa. This is expected to generate the demand for the treatment of end stage renal disease in the region.

Asia Pacific is also expected to expand at the highest CAGR during the forecast period due to factors such as growth in the aging population, various lifestyle stress, improvement in the quality of diagnosis, and increasing patient affordability. Middle East & Africa is estimated to closely follow Asia Pacific in terms of CAGR over the forecast period. The African-Middle East ethnicity has been observed to be the most prone to CKD in the global population. The incidence rate of CKD among the African-Middle Eastern countries stands at 18-23% of the total population, which is significantly higher than global population.

End Stage Renal Disease Market Share Insights: End Stage Renal Disease Market

Major players operating in the industry for end stage renal disease include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd. Market players are focusing on the launch of innovative products and accessories, growth strategies, and technological advancements.

For instance, in October 2019, Fresenius Medical Care has received breakthrough device designation by the U.S. FDA for its new hemodialysis machine that aims to prevent blood clotting without the use of any medication. Additionally, few market players are introducing technologically advanced products to gain competitive advantage over their competitors. Advancements in the field of end stage kidney disease devices are anticipated to boost the market growth over the forecast period. This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2016 to 2027. For the purpose of this study, Trusted Business Insights has segmented the global end stage renal disease market report on the basis of treatment and region:

Treatment Outlook (Revenue, USD Million, 2016 2027)

Looking for more? Check out our repository for all available reports on End Stage Renal Disease in related sectors.

Quick Read Table of Contents of this Report @ End Stage Renal Disease Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

Here is the original post:
End Stage Renal Disease Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19 - Eurowire